top of page
Colorful Disks

Luciferase Reporter Cell Lines for Monitoring
TF Binding and Activation

All Stable Cell Line
Product Catalogue

Gene function analysis, target discovery and validation, assay development, and compound screening often need cell-based assays.  Stable cell lines that are engineered to express a gene of interest via transgene integrations into the host genome provide an efficient approach to conduct such analysis. 

At Signosis, we help researchers save time and labor in generating and validating stable cell lines so scientists can spend more effort on solving the big questions.  We offer a wide selection of validated Firefly luciferase reporter cell lines that measure transcription factor activity as a read-out for various signaling pathways.

We also offer Gaussia luciferase reporter cell lines, a special type of luciferase that is naturally secreted from cells, which allows for the measurement of reporter activity in the media without harming the cells. 

 

Principle

TF luciferase reporter stable cell line utilizes artificial promoter constructs to drive luciferase expression.  The promoter region can consists of multiple repeats of a cis-element TF binding site, a DNA fragment from the promoter region of a known TF downstream gene, or a DNA fragment containing putative/known TF binding sites.  There are several ways that a TF can be activated, such as through extracellular stimuli or through intracellular signaling pathways.  Once activated, the TF translocates to the nucleus and often interacts with relevant co-factors to drive gene expression.  Once luciferase is expressed, it can generate light in an enzymatic assay and the amount of light measured is positively correlated with the level of TF activation

Benefits

High Sensitivity & Responsiveness

Each cell line is validated to induce a strong reporter signal in response to stimuli, and is highly responsive to our Firefly Luciferase Substrate.

​​

Routine Mycoplasma Testing

All cell lines tested negative for mycoplasma.

Consistent

​

TF reporter construct is stably integrated into the genome to avoid experimental/cell-to-cell variations.

We also offer our own Firefly Luciferase Substrate which can generate a strong signal.

Time-Saving

 

Cell line can be used for experiments right away to study different signaling pathways.

Target
Product
SKU
Price (USD$)
AARE
SL-0066
3870
AARE
SL-0065
3870
AP-1
SL-0019
2904
AP1
SL-0085
3870
AR
SL-0008
3870
ATF4
SL-0079
2904
ATF4
SL-0080
2904
ATF6
SL-0024
2904
ATF6
SL-0084
3870
ATF6
SL-0082
3870
CHOP
SL-0083
3870
CHOP
SL-0025
2904
CREB
SL-0020
2904
CREB
SL-0031
2904
Control
SL-0039
1165
Control
SL-0038
1165
ELK
SL-0077
2904
ELK-TAD
SL-0040
2904
ELK-TAD
SL-0041
2904
ER Stress-ERSE
SL-0068
3870
ER Stress-ERSE
SL-0067
3870
ER Stress-ERSE
SL-0069
3870
Estrogen Receptor
SL-0002
2904
FXR
SL-0055
4245
GAS/Stat1
SL-0074
3870
Glucocorticoid Receptor
SL-0009
3870
Glucocorticoid Receptor
SL-0021
3870
HIF
SL-0027
2904
HIF
SL-0005
2904
HIF
SL-0034
2904
HIF
SL-0023
2904
IFNa
SL-0052
2904
IRF
SL-0049
2904
IRF
SL-0035
2904
MRF
SL-0053
2904
NFAT
SL-0032
2904
NFAT
SL-0029
2904
NFAT
SL-0018
2904
NFAT
SL-0078
2904
NFkB
SL-0043
2904
NFkB
SL-0001
2904
NFkB
SL-0012
2904
NFkB
SL-0026
2904
NFkB
SL-0050
3870
NFkB
SL-0006
2904
NFkB
SL-0033
2904
NFkB
SL-0014
2904
NFkB
SL-0017
2904
NFkB
SL-0013
3870
NRF2/ARE
SL-0046
2904
NRF2/ARE
SL-0047
2904
NRF2/ARE
SL-0010
2904
NRF2/ARE
SL-0042
2904
RAR
SL-0086
3870
SMAD/BMP
SL-0051
3870
SMAD/TGFbeta
SL-0030
3870
SMAD/TGFbeta
SL-0016
3870
Stat1
SL-0004
2904
Stat3
SL-0071
3870
Stat3
SL-0081
3870
TCF/LEF
SL-0022
2904
TCF/LEF
SL-0028
2904
TCF/LEF
SL-0015
3870
XRE
SL-0075
2904
p53
SL-0007
3870
p53
SL-0072
3870
p53
SL-0011
3870

Signaling Pathways

Cell Lines

Androgen Receptor/ AR

Targeted therapies for prostate cancer and other androgen-related diseases.

Calcineurin/NFAT
T Cell Activation

Activation of T Cells in immune response via calcium signaling.

ER Stress/ATF4
ATF6/CHOP/ERSE

 

Development of treatments for type 2 diabetes and neurodegenerative disorders.

Glucocorticoid
Receptor/GR

Development of treatments for autoimmune and inflammatory diseases.

Hypoxia
HIF

Development of treatments for cancer and ischemic diseases.

Inflammation
NF-κB

Development of treatments for cancer, diabetes, and inflammation.

JAK/STAT1/2
IFNα/ISRE

Development of treatments for cancer and autoimmune disorders.

MAPK/ERK
ELK

Development of treatments for cancer and autoimmune disorders.

Metabolism
FXR/RAR/AARE

Development of drugs for treating various metabolic diseases, including liver disease and diabetes.

SMAD 2/3/4
TGF-β

Development of treatments for cancer and fibrosis.

Wnt/β-Catenin
TCF/LEF

Development of treatments for cancer and bone disorders.

Antioxidant Pathway/ NRF2

Development of treatments for Alzheimer's, Parkinson's, and cancer.

cAMP/PKA
CREB

Development of drugs for treating various diseases, including cancer, diabetes, and inflammation.

Estrogen
Receptor

Targeted therapies for breast cancer and other estrogen-related diseases.

Heavy Metal Stress
MRF

Development of treatments for heavy metal toxicity.

Immune Response
IRF

Development of treatments for autoimmune and inflammatory diseases.

JAK/STAT1
IFNgamma

Development of drugs for treating various diseases, including cancer and autoimmune disorders.

JAK/STAT3
 

Development of drugs for treating various diseases, including cancer and inflammation.

MAPK/JNK
AP-1

Development of drugs for treating various diseases, including cancer, diabetes, and inflammation.

DNA Damage
p53

Development of treatments for cancer and genetic disorders.

SMAD 1/5/8
BMP

Development of treatments for bone and cartilage disorders.

Xenobiotic Stress
Toxicity/XRE/AHR

Development of treatments for xenobiotic toxicity and related diseases.

Products